This page shows the latest Tagrisso news and features for those working in and with pharma, biotech and healthcare.
In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib).
For the year to date, AZ’s oncology franchise has grown by 24% to $8.18bn, driven by strong growth of its EGFR tyrosine kinase inhibitor Tagrisso (Osimertinib) and immunotherapy Imfinzi
In a group of 45 patients who had relapsed following treatment with AstraZeneca’s Tagrisso (osimertinib), Janssen’s combination treatment produced a 36% ORR, with one complete response and 15 partial ... The recommended dose is now being studied in a
AstraZeneca’s Tagrisso cuts the risk of EGFR-positive lung cancer patients developing brain metastases, according to new data revealed by the company on Saturday. ... Tagrisso should become the standard of care in the adjuvant setting, just as it is
Tagrisso (osimertinib), Imfinzi (durvalumab) and Lynparza (olaparib).
Other rivals include AstraZeneca with small-molecule candidate savolitinib in mid-stage testing for NSCLC patients who have progressed after treatment with its EGFR inhibitor Tagrisso (osimertinib) as well as in ... combination. MET is known as a
More from news
Approximately 29 fully matching, plus 57 partially matching documents found.
Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... Tagrisso’s growth as it
Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... Two leading examples of this are
Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... EvaluatePharma forecasts that Lynparza (now co
In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Liang had been instrumental in building up the company’s
targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.